CLINICAL PROTOCOL AND DATA MANAGEMENT ABSTRACT Knight Clinical Protocol and Data Management (KCPDM) provides centralized support for the efficient and effective conduct of high-quality translational and clinical oncology research. The Knight Cancer Institute has expanded and restructured the KCPDM since 2010 to increase capacity and continue to enhance the quality of the services. The organization's 93 staff members offer comprehensive services including regulatory compliance, auditing and monitoring, protocol development, trial coordination, data management, research nursing, administration and financial operations, and reporting. In 2015, KCPDM administered 243 interventional clinical research studies and accrued 700 subjects on trial. The Knight Data and Safety Monitoring Plan (DSMP) focuses on oversight of subject safety and data integrity of studies not monitored by an external party. The plan was revised in 2015 to incorporate risk-based monitoring for Knight clinical research studies. Key elements of the monitoring includes a trial-specific monitoring plan addressing all critical elements of the research, implementation of the plan as evidenced through trial progress reports and the auditing and monitoring function. The Knight is committed to serving all residents in our catchment area, the state of Oregon. The Institute increased the rate of accrual of women in interventional clinical trials from 43% to 50% during the past five years. Minority group accruals continue to be in line with the Oregon Health & Science University (OHSU) cancer population. OHSU is actively engaged in clinical research in children with 53 interventional, treatment studies including subjects less than 18 years of age open in 2015 at OHSU. Among Oregonians accrued to interventional studies, 29% resided in rural regions which is similar to the rural population of our catchment area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA069533-20S1
Application #
9758301
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
Project End
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
20
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Lane, Ryan S; Femel, Julia; Breazeale, Alec P et al. (2018) IFN?-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 215:3057-3074
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Medler, Terry R; Murugan, Dhaarini; Horton, Wesley et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell 34:561-578.e6
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Davare, Monika A; Henderson, Jacob J; Agarwal, Anupriya et al. (2018) Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res 24:6471-6482
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
Watson, Spencer S; Dane, Mark; Chin, Koei et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Syst 6:329-342.e6

Showing the most recent 10 out of 277 publications